The case for & against
Bull & Bear analysis
Atara Biotherapeutics (NASDAQ: ATRA) is a biotechnology firm specializing in innovative allogeneic T-cell therapies, particularly targeting severe diseases such as progressive multiple sclerosis (MS) and Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder (PTLD). The company is actively involved in developing prominent therapies like TAP-Cell (rebranded as EBVALO) and ATA-188, positioning itself in the growing cellular immunotherapy landscape. Atara aims to address significant unmet medical needs through its unique therapies, largely supported by strategic partnerships, particularly its collaboration with Pierre Fabre Pharmaceuticals.
Bull says
- ↑Expanded partnership with Pierre Fabre targets $640M in milestone payments
- ↑TAP-Cell projected to exceed $500M peak U.S. sales for EBV+ PTLD
- ↑ATA-188 interim readout in Nov ’23 could validate MS therapy efficacy
- ↑40% planned cash burn reduction extends runway into Q3 2025
- ↑Institutional interest strong; positive momentum signals growing investor support
- ↑Upcoming $100M BLA milestone payment expected Q2 2024
Bear says
- ↓Earnings yield negative and low profitability raise sustainability doubts
- ↓FDA may require additional studies, delaying TAP-Cell BLA approval
- ↓Intensifying CAR-T competition threatens market share and first-mover edge
- ↓30% workforce cut increases execution risk and could slow trials
- ↓High leverage and negative growth factors heighten financial risk
- ↓Cash runway tied to milestones; failure to hit targets risks liquidity crunch
Earnings Call · Q4 2021 · Mgmt. Guidance
Transcript signals
Bull points
- TAP-Cell has the potential to be the first of its kind, which may require a unique approach to approval similar to what was achieved by Otologous CAR-T.
- 18188. to work really across any type of multiple sclerosis
- We have, as we said, established a safe and effective acceptable range of values for each attribute. So we have ways to establish the specification of a commercial product that will support a safe and effective product.
Bear points
- as a result of such preliminary feedback received from the FDA, ATARA does not currently expect to file a BLA for TAPCEL in Q2 2022.
- the anticipated $100 million payable to Atara upon closing of the strategic transaction with Fuji, will be sufficient to fund the company plan operation into the fourth quarter of 2023.
- bear cases